CT-fibrosis score: development and internal validation for identifying advanced fibrosis in metabolic dysfunction-associated steatotic liver disease
Abdominal Radiology · 03.11.2026
DOI: 10.1007/s00261-026-05825-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Abdominal Radiology, online erschienen am 03.11.2026. Verfasst von Grant Kokenberger und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, University of Pittsburgh, Pittsburgh, USA. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
Purpose
Advanced fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD) involves metabolic and anatomic remodeling beyond the liver. We developed and internally validated an interpretable CT-based score integrating abdominal body-composition and organ measurements and compared it with the Fibrosis-4 (FIB-4) index.
Methods
We retrospectively studied 151 patients with biopsy-confirmed MASLD (86 advanced [F3–F4], 65 early-stage [F0–F2] fibrosis). Deep learning-based segmentation quantified abdominal adipose tissue, skeletal muscle, bone, liver, and spleen measurements. The CT-Fibrosis Score was developed using repeated (50×) stratified 5-fold cross-validation, with imputation, standardization, and feature selection confined to each training fold and inner 5-fold cross-validation for hyperparameter selection. Performance was based on out-of-fold predictions and compared with FIB-4 using the DeLong test. Sensitivity analyses addressed missing data, age dependence, and ascites.
Results
Four features were consistently selected: age, bone-to-abdominal-cavity volume ratio, visceral adipose tissue (VAT) density, and spleen index. The CT-Fibrosis Score achieved an out-of-fold AUC of 0.77 (95% CI 0.69–0.85). Among 141 patients with an available FIB-4 score, no significant difference was detected between the CT-Fibrosis Score (AUC 0.76) and FIB-4 (AUC 0.79; difference − 0.03, 95% CI − 0.11 to + 0.04; p = 0.37); this comparison was not powered for non-inferiority. Adding the CT-Fibrosis Score to FIB-4 did not improve discrimination (AUC 0.80 vs. 0.79; difference + 0.003, 95% CI − 0.04 to + 0.05; p = 0.90), with the confidence interval excluding an improvement greater than approximately 0.05.
Conclusion
The CT-Fibrosis Score achieved moderate discrimination for advanced fibrosis but did not improve discrimination when added to FIB-4. External validation in an unselected population undergoing CT for non-hepatic indications is required before any opportunistic application.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, University of Pittsburgh, Pittsburgh, USA.
- Department of Medicine, University of Pittsburgh, Pittsburgh, USA.
- Department of Bioengineering, University of Pittsburgh, Pittsburgh, USA.
- Department of Research, University of Miami, Coral Gables, USA.
- Pittsburgh Liver Research Center, University of Pittsburgh, Pittsburgh, USA. behajx@UPMC.EDU.
- Department of Radiology, University of Pittsburgh, Pittsburgh, USA. XIM94@pitt.edu.
ORCID-Profile: Grant Kokenberger
Zitieren
APA
Kokenberger, G., Almetwali, O., Yu, T., Singh, J., De La Torre, A. L. C., Sethuraman, S., Leader, J. K., Pu, J., Behari, J., & Meng, X. (2026). CT-fibrosis score: development and internal validation for identifying advanced fibrosis in metabolic dysfunction-associated steatotic liver disease. Abdominal Radiology. https://doi.org/10.1007/s00261-026-05825-2
Vancouver
Kokenberger G, Almetwali O, Yu T, Singh J, De La Torre ALC, Sethuraman S, et al. CT-fibrosis score: development and internal validation for identifying advanced fibrosis in metabolic dysfunction-associated steatotic liver disease. Abdominal Radiology. 2026. doi:10.1007/s00261-026-05825-2
BibTeX
@article{Kokenberger2026,
author = {Kokenberger, Grant and Almetwali, Omar and Yu, Tong and Singh, Jatin and De La Torre, Adriana L Cifuentes and Sethuraman, Shruthi and Leader, Joseph K and Pu, Jiantao and Behari, Jaideep and Meng, Xin},
title = {CT-fibrosis score: development and internal validation for identifying advanced fibrosis in metabolic dysfunction-associated steatotic liver disease},
journal = {Abdominal Radiology},
year = {2026},
doi = {10.1007/s00261-026-05825-2}
}
EUVIMED